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TO THE EDITOR
In this study, we present an animal
model that swiftly recreates one of the
most frequent human autoimmune dis-
orders, alopecia areata (AA) (Safavi
et al., 1995; Harries et al., 2010; Alli
et al., 2012; Gilhar et al., 2012), within
transplanted healthy human skin
(Figure 1a–c,g).
AA is a CD8þ T cell–dependent
autoimmune hair loss disorder, which
is associated with other autoimmune
diseases. It results from inflammatory
cell infiltrates that attack growing (ana-
gen) hair follicles in association with a
collapse of the normal immune privilege
(IP) that healthy hair follicles enjoy
(Gilhar et al., 1998; McElwee et al.,
2005; Paus et al., 2005; Alli et al., 2012;
Gilhar et al., 2012). As in other auto-
immune diseases, IFN-g and subs-
tance P are key inducers of hair follicle
IP collapse (Ito et al., 2004; Peters et al.,
2007; Siebenhaar et al., 2007; Gilhar
et al., 2012).
AA patients demonstrate excessive
natural killer (NK) cell activities, as well
as overexpression of NK-activating
receptors (NKG2D) and NKG2D-acti-
vating ligands (MICA and ULBP3) (Ito
et al., 2008; Petukhova et al., 2010).
NKG2D is expressed on NK and NKT
cells, as well as on some T lymphocytes,
and its ligands are implicated in
other common autoimmune diseases
(Gambelunghe et al., 2007; Andersson
et al., 2011).
Therefore, we asked whether the
transfer of human peripheral blood
mononuclear cells (PBMCs) greatly
enriched for NKG2Dþ and CD56þ
cells suffices to induce AA-like hair loss
in healthy human skin transplanted onto
immunocompromised mice, even when
PBMCs are derived from healthy donors.
Fifty-five C.B-17/IcrHsd-scid-bg mice
were used in this study. Punch biopsies
from normal hairy human scalp were
obtained from each donor during rou-
tine face-lift surgery with written infor-
med consent and ethics approval, and
were grafted onto SCID mice. Thereafter,
either allogeneic or autologous PBMCs
enriched for NKG2Dþ or CD56þ T
cells (CD4, CD8) from healthy donors
were injected once subcutaneously
(Figure 1g).
Briefly, PBMCs were isolated from
healthy donors and then cultured with
100 U ml1 IL-2 (2 weeks)/phytohemag-
glutinin (PHA) (10mg ml1). Alterna-
tively, PBMCs were cultured with IL-2
(100 U ml1). After 14 days of incuba-
tion, NKG2D/CD56-enriched cells were
incubated with anti-CD56 antibodies
conjugated to ferromagnetic microbeads
(Miltenyi Biotec GmbH, Bergisch Glad-
bach, Germany) and directed through a
cell separation column containing a
magnetic field (Miltenyi Biotec GmbH).
In addition, CD56-depleted cells were
prepared for injection.
The NKG2D/CD56 cell population
expressed the surface markers shown
in Figure 2a, including heterogeneous
NK cell markers, and exhibit NK cyto-
toxicity (Gilhar et al., 2002). Treatment
with high-dose IL-2 (100 U ml1) led
to a significantly greater enrichment
of NKG2Dþ and CD56þ following
culture of PBMCs than PHA treatment
(Supplementary Figure S1 online).
Three months after human skin
graft transplantation, 7106 of these
NKG2D/CD56-enriched cells were
injected (note that in the humanized
mouse model for psoriasis these cells
are given intradermally into split-thick-
ness skin grafts (Gilhar et al., 2002,
2011), whereas they are injected into
the subcutis of 3-mm full-thickness scalp
skin grafts in the present model).
Strikingly, 3–5 weeks after cell injec-
tion, all the characteristic clinical and
histological features of human AA were
reproduced. Although impressive hair
growth was observed in human scalp
skin grafts before cell injection (Figure 1b),
marked, localized hair loss was seen
exclusively in scalp grafts treated with
PBMCs enriched for NKG2Dþ and
CD56þ cells (Figure 1c), but in none
of the control groups (i.e., PBMCs non-
specifically activated with PHA, and
activated PBMCs depleted for CD56þ
cells) (Supplementary Figure S2 online).
Exactly as in human AA (Gilhar et al.,
2012), dense perifollicular infiltrates of
CD4þ or CD8þT cells around proxi-
malanagen hair follicles (Supplementary
Figure S3 A–F online) and collapse of
hair follicle IP (Figure 2b–e) were seen.
Importantly, hair loss occurred irrespec-
tive of whether the mice had been injected
with autologous or allogeneic NKG2Dþ /
CD56þ cell–enriched PBMCs. Only
injection of stimulated PBMCs that were
highly enriched for activated NK/NKT
cells mimicked human AA (Supplementary
Figure S3 A–F online). Besides their
IP-collapse–promoting activities, the
IFN-g-secreting NK/T cells may directly
inhibit hair growth as IFN-g potently
induces catagen (Ito et al., 2005).
Although CD56þ cells are critical for
inducing the AA phenotype in this model,
the key pathogenic subpopulation(s) in
the injected cell collective, and the
spectrum of cytokines secreted by them
(e.g., IFN-g) (Gilhar et al., 1998, 2012)
(Figure 2f,g), remain unknown. How-
ever, this model already offers a
superior preclinicial AA research tool
and allows the preclinical testing
of new candidate AA therapies (see
supplementary text online). Moreover,
this model provides functional support
for the concept that NKG2Dþ and/or
CD56þ cells (and likely NKG2D-
Abbreviations: AA, alopecia areata; IP, immune privilege; NK, natural killer; PBMCs, peripheral blood
mononuclear cells; PHA, phytohemagglutinin
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stimulating ligands such as MICA and
ULPB3) have an important role in AA
pathogenesis (Ito et al., 2008; Petukhova
et al., 2010).
This humanized mouse model of AA,
which uses healthy human skin and
PBMCs from healthy donors, questions
whether certain genetic and environ-
mental factors predisposing to the devel-
opment of AA are really indispensable
for inducing the AA phenotype. Cer-
tainly, the current model offers to
welcome new opportunities to dissect
the specific contributions of genetic and
environmental factors to AA patho-
biology (for additional background, dis-
cussion, and references, see Supple-
mentary text online).
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Figure 1. Alopecia areata (AA) in patients and in the humanized AA mouse model. (a) Characteristic hair phenotype of a female patient with AA (Gilhar et al.,
2012). (b) Normal hair growth in a human scalp skin transplanted onto beige SCID mice. (c) Complete AA-like hair loss in human skin graft injected with
peripheral blood mononuclear cells (PBMCs) greatly enriched for NKG2Dþ and CD56þ cells (details: see Figure 2a). (d, f) Dense perifollicular and intrafollicular
lymphocytic infiltrate in AA patients (d). The same is seen in human skin graft injected with PBMCs enriched for NKG2Dþ and CD56þ cells (f). (e) Normal
human scalp hair follicles in a control graft injected with phytohemagglutinin-activated PBMCs. DP, dermal papilla; HB, hair bulb; HS, hair shaft. Bar¼ 100mm.
(g) Overview of the humanized AA mouse model. (1) Punch biopsies (3 mm) are taken from a healthy donor with normal hair growth under local anesthesia.
(2) Three biopsies are inserted into small incisions made on the back of a beige SCID mouse. (3) About 2–4 weeks after the transplantation, the expected hair loss
(telogen effluvium) is seen. After that, the transplants are treated twice daily with 5% topical minoxidil to enhance hair regrowth (Harries et al., 2010). (4) Optimal
hair regrowth is seen 2–3 months after scalp skin transplantation. (5) Allogeneic or autologous PBMCs from peripheral blood from healthy donors are cultured with
high-dose IL-2 (100 U ml 1). Lymphocyte lines with natural killer (NK) activity and heterogeneous T cells with NK phenotype, including CD56þ and NKG2Dþ ,
are generated by culture of PBMCs from normal donors in 100 U ml 1. This enriching culture with CD56þ and NKG2Dþ cells (47%) is injected (7106 ) once
into the lower part of the full-thickness skin grafts. This induces the characteristic macroscopic and microscopic features of AA (Gilhar et al., 2012) within
previously normal human scalp skin transplants.
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Figure 2. The role of CD56þ and NKG2Dþ cells in the induction of alopecia areata in the humanized mouse model. (a) Flow cytometry analysis of
peripheral blood mononuclear cells (PBMCs) cultured with high-dose IL-2 (100 U ml1) demonstrated a significant enrichment in NKG2Dþ and CD56þ
cells among CD4þ and CD8þ T cells. (b, c) Immunohistochemistry revealed the characteristic signs of hair follicle immune privilege collapse (Ito et al.,
2008; Gilhar et al., 2012) in hair follicles affected by alopecia areata (AA) after injection of PBMCs enriched for NKG2Dþ and CD56þ cells, as
indicated by ectopic major histocompatibility complex (MHC) class I expression (Ito et al., 2008). (d, e) Immune privilege collapse was also evident from the
ectopic expression of MHC class II (Ito et al., 2008). (f, g) The fact that many of the perifollicullar lymphocytic cells in the test mice were strongly positive
for IFN-g supports the widely accepted central role of IFN-g in AA pathogenesis (Gilhar et al., 2012). (h, i) Interestingly, the injection of activated PBMCs
enriched for NKG2Dþ cells was associated with a prominent upregulation of one classical NKG2D ligand, MICA (Ito et al., 2008; Petukhova et al.,
2010), possibly as a result of excessive IFN-g secretion (see f, g). (j, k) Indeed, a dense intrafollicular and perifollicular NKG2Dþ cells infiltrate is
observed in the treated mice, which enables NKG2D/MICA engagement (see h, i). (l, m) Double immunostaining revealed CD8þ /NKG2Dþ T cells
around lesional hair follicles (arrows) after injection of PBMCs enriched for NKG2Dþ and CD56þ cells. Bar¼ 100mm. DP, dermal papilla; HB, hair bulb;
HS, hair shaft.
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High Anti-Staphylococcal Antibody Titers in Patients with
Epidermolysis Bullosa Relate to Long-Term Colonization
with Alternating Types of Staphylococcus aureus
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TO THE EDITOR
Patients with the blistering disease epi-
dermolysis bullosa (EB) develop wounds
that are highly susceptible to bacterial
colonization. Recently, we reported that
over 75% of the EB patients sampled
at one particular point of time were
colonized with Staphylococcus aureus
(van der Kooi-Pol et al., 2012). To
determine possible changes in S. aureus
colonization over time, swabs were
collected from the nares, throats, and
wounds of 61 EB patients at three time
points during a period of B2 years. All
S. aureus isolates were typed by
multiple-locus variable number of
tandem repeats analysis (MLVA) and
spa typing. This revealed major
fluctuations in the S. aureus types
sampled from individual EB patients. In
addition, blood samples were obtained
from 13 EB patients to determine their
IgG levels against 43 virulence factors
or whole cells of S. aureus. Overall, the
sera of EB patients contained higher
anti-staphylococcal IgG levels than
those of healthy individuals. Specifi-
cally, this applied to IgGs against
nine important virulence factors,
including the superantigens (SAgs)
staphylococcal enterotoxin M (SEM),
SEN, and SEO. Notably, EB patients
carrying different S. aureus types
contained higher levels of anti-
staphylococcal antibodies than EB
patients colonized by only one type.
Abbreviations: EB, epidermolysis bullosa; ET, exfoliative toxin; HlgB, gamma-hemolysin B; IsaA,
immunodominant antigen A; Isd, iron-responsive surface determinant; Luk, leukocidin; LytM,
peptidoglycan hydrolase; MFI, median fluorescence intensity; MLVA, multiple-locus variable number of
tandem repeats analysis; Nuc, endonuclease; SAgs, superantigens; SasG, S. aureus surface protein G; SCIN,
staphylococcal complement inhibitor; SE, staphylococcal enterotoxin
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